A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Broad-based skin cancer screening may strain healthcare resources and lead to overdiagnosis, but it may also help catch more ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron Pharmaceuticals Inc. closed 49.58% below its 52-week high of $1,211.20, which the company achieved on August 27th.

This was the stock's second consecutive day of losses.